InterAx and Alveus Announce Strategic Licensing and Research Agreement to Develop a Differentiated Therapeutic Candidate for a Metabolic Disease
Friday, January 16, 2026
InterAx Biotech Ltd (“InterAx”) and Alveus Therapeutics Inc. (“Alveus”) today announced a strategic licensing and research collaboration agreement to develop a differentiated small molecule candidate for metabolic disease to offer a durable weight loss therapy with superior tolerability.
This collaboration is part of a joint research effort into a target and modality of established but untapped therapeutic interest, combining InterAx’s Deep Signal™ discovery platform, designed to optimize candidates for superior signaling profiles, with Alveus’ deep R&D expertise and leadership in obesity, diabetes, and cardiometabolic diseases.
The original text of this announcement, written in the source language, is the official and authoritative version. Translations are provided solely for the reader's convenience and must refer to the original language text, which is the only legally valid version.
Contacts
InterAx Biotech Ltd
Media Contact: Luca Zenone,contact@interaxbiotech.com
Investor and Media Contacts
Alveus Therapeutics
Media
Sasha Damouni Ellis, Damouni Group LLC
sasha@damounigroup.com
Investors:
Victoria Igumnova, Meru Advisors LLC
vigumnova@meruadvisors.com
Source: businesswire.com
